Greece to Spend 780 Mln Euros to Protect Marine Biodiversity, Says PM

Plastic waste is pictured at the bottom of the sea, off the island of Andros, Greece, July 20, 2019. (Reuters)
Plastic waste is pictured at the bottom of the sea, off the island of Andros, Greece, July 20, 2019. (Reuters)
TT

Greece to Spend 780 Mln Euros to Protect Marine Biodiversity, Says PM

Plastic waste is pictured at the bottom of the sea, off the island of Andros, Greece, July 20, 2019. (Reuters)
Plastic waste is pictured at the bottom of the sea, off the island of Andros, Greece, July 20, 2019. (Reuters)

Greece is pushing ahead with 21 initiatives worth 780 million euros ($830.9 million) to protect marine biodiversity and tackle coastal pollution, Prime Minister Kyriakos Mitsotakis said on Monday ahead of an international conference.

Greece, which includes thousands of islands and which has the longest Mediterranean coastline of any littoral state, said last week it plans to create two marine parks, one in the Ionian Sea and one in the Aegean Sea, as part of the initiatives.

"Quietly but methodically, Greece is playing a leading role in the defense against dramatic climate changes, which are proven to affect every region and every activity," Mitsotakis said in an article published in Kathimerini newspaper.

Greece plans to present its national strategy on marine biodiversity protection at the "Our Ocean" conference, which Athens will host this year and which will be attended by about 120 countries.

More than 400 new commitments amounting to $10 billion will be announced during the conference, said a government official, speaking on condition of anonymity.

The European Union's Copernicus Climate Change Service said last month that ocean temperatures hit a record high in February, in a dataset that goes back to 1979. Overfishing and plastic pollution are also major threats to oceans.

Plastics entering the world's oceans could nearly triple by 2040 if no further action is taken, research has shown.

Greece wants to reduce plastic litter in the water by 50% and microplastics by 30% by 2030, the government official said.

The Greek marine parks, whose boundaries will be defined after scientific research by early 2025, will cover 32% of Greece's waters, Mitsotakis said. Greece has legislated the expansion of marine protected areas to 30% of its territorial waters by 2030.

The plan for a marine park in the Aegean Sea has irritated neighboring Türkiye, which said last week that it was not willing to accept a possible "fait accompli on geographical features whose status is disputed". In response, Greece accused Türkiye of "politicizing a purely environmental issue".

NATO allies Greece and Türkiye have long been at odds over a range of issues including maritime boundaries and claims over their continental shelves in the Mediterranean.

Mitsotakis said other initiatives underway include campaigns to curb plastic pollution, constructing charging stations at 12 ports for electric vessels and setting up a monitoring system for protected marine areas because fishing practices that damage the seabed will be banned. Greece wants to ban bottom trawling in all marine protected areas by 2030, the official said.



Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”